These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 25267524)

  • 1. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
    Hobeika L; Self SE; Velez JC
    BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
    Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
    BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
    Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
    Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib-induced thrombotic microangiopathy. A case report.
    Scheggi V; Merilli I; Cesaroni E; Alterini B
    J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
    Catanese L; Link K; Rupprecht H
    BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Carfilzomib in multiple myeloma relapses].
    Bay JO
    Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287
    [No Abstract]   [Full Text] [Related]  

  • 8. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
    Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
    J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
    Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
    Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
    Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
    Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
    Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
    J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
    Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
    Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
    Khan ML; Reeder CB; Kumar SK; Lacy MQ; Reece DE; Dispenzieri A; Gertz MA; Greipp P; Hayman S; Zeldenhurst S; Dingli D; Lust J; Russell S; Laumann KM; Mikhael JR; Leif Bergsagel P; Fonseca R; Vincent Rajkumar S; Keith Stewart A
    Br J Haematol; 2012 Feb; 156(3):326-33. PubMed ID: 22107129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma, version 1.2013.
    Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Illizaliturri F; Huff CA; Kassim A; Krishnan AY; Liedtke M; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Yunus F; Shead DA; Kumar R
    J Natl Compr Canc Netw; 2013 Jan; 11(1):11-7. PubMed ID: 23307977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
    Schmielau J; Teschendorf C; König M; Schmiegel W; Graeven U
    Leuk Lymphoma; 2005 Apr; 46(4):567-9. PubMed ID: 16019485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
    Fujimori C; Hagino T; Osanai S; Sano S; Saga R; Hidai H; Kurimoto M; Murai Y; Akiyama H; Motomura S
    Rinsho Ketsueki; 2022; 63(12):1626-1632. PubMed ID: 36653134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report.
    Cassol CA; Williams MPA; Caza TN; Rodriguez S
    Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.